Retinal hemorrhages in anastrozole users.
Alvin Eisner1, Julie Falardeau, Maureen D Toomey
1Neurological Sciences Institute, Oregon Health & Science University, Beaverton, Oregon 97006, USA. eisnera@ohsu.edu
Summary
Women using anastrozole, an aromatase inhibitor, showed a higher incidence of retinal hemorrhages compared to controls. This finding suggests a potential link between estrogen depletion and ocular vascular changes.
Area of Science:
- Ophthalmology
- Oncology
- Endocrinology
Background:
- Anastrozole is an aromatase inhibitor used in breast cancer therapy.
- Estrogen plays a role in vascular health.
- Potential ocular side effects of anastrozole are not well-established.
Purpose of the Study:
- To investigate the association between anastrozole use and retinal hemorrhages.
- To compare hemorrhage rates in anastrozole users versus tamoxifen users and controls.
Main Methods:
- Fundus photography was used to assess for retinal hemorrhages.
- Ophthalmologists masked to treatment status evaluated the photographs.
- Study included anastrozole users, tamoxifen users, and non-endocrine therapy controls.
Main Results:
- Retinal hemorrhages were observed in four anastrozole users.
- No hemorrhages were found in contemporaneous tamoxifen users or control subjects.
- Hemorrhages were located within the posterior pole, including flame and blot types.
Conclusions:
- Anastrozole use is associated with an increased prevalence of retinal hemorrhages.
- Hemorrhages may indicate vascular compromise or vitreoretinal traction due to estrogen depletion.
- Further prospective studies with larger cohorts are warranted.
